Evolus to Hold Investor Day on September 12, 2024
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has announced its upcoming Investor Day scheduled for September 12, 2024 in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The event will be hosted at the “SECOND Floor” venue located at 849 6th Ave,
During the event, Evolus’ management team will provide in-depth presentations and discussions of the Company’s strategic vision, investment strategies, growth levers, and financial outlook. The formal presentations will be followed by a Q&A session.
The Investor Day is open to the investment community and pre-registration is required. To pre-register for the event, please visit the registration page of the Evolus Investor Day website here. Confirmation and additional event details will be provided to registered attendees. The live webcast of the event will also be available on the Evolus Investor Day website.
Following the event, a replay of the webcast and supporting materials will be made available on the Investor Relations page of the Evolus website here.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731501783/en/
Investors:
Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications
Phone: (248) 202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus